The Monoglyceride Lipase pipeline drugs market research report outlays comprehensive information on the Monoglyceride Lipase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Monoglyceride Lipase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System which include the indications Substance (Drug) Abuse, and Unspecified Neurologic Disorders. It also reviews key players involved in Monoglyceride Lipase targeted therapeutics development with respective active and dormant or discontinued products.
The Monoglyceride Lipase pipeline targets constitutes close to ten molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 6, 2, and 2 respectively.
Monoglyceride Lipase overview
Monoglyceride lipase (MGLL) is an enzyme that plays a crucial role in the metabolism of lipids (fats) in the body. It is primarily involved in the breakdown of monoglycerides, which are intermediates in the digestion and absorption of dietary fats. It converts mono acyl glycerides to free fatty acids and glycerol, and hydrolyzes the endocannabinoid 2-arachidonoylglycerol, and thereby contributes to the regulation of endocannabinoid signaling, nociperception, and perception of pain.
For a complete picture of Monoglyceride Lipase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
